Nuvectis Pharma Q3 EPS $(0.37) Misses $(0.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Nuvectis Pharma reported Q3 losses of $(0.37) per share, missing the analyst consensus estimate of $(0.34) by 8.82 percent. This is an 11.9 percent increase over losses from the same period last year.
November 08, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nuvectis Pharma's Q3 earnings per share of $(0.37) missed the analyst consensus estimate, which may negatively impact the stock in the short term.
Nuvectis Pharma's Q3 earnings per share missed the analyst consensus estimate. This underperformance is often seen as a negative sign by investors, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100